Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration

NCT01367444 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01367444
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01367444 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIA Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration
Lead sponsor
Sanofi
Phase
Phase 1/2
Overall status
Terminated
Start date
June 8, 2011
Completion date
August 16, 2019
Enrollment
27 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

stargardt's disease